President – Prof. Siegfried Kasper, Austria
Dr. Siegfried Kasper is Professor of Psychiatry and Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. Born in Salzburg, Austria, he was educated at the medical schools of the University of Innsbruck, Austria and the Universities of Freiburg and Heidelberg, Germany. Dr. Kasper gained clinical and research experience in psychiatry at the Central Institute of Mental Health, Mannheim, Germany, the Psychiatric Department of the University of Heidelberg, Germany, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and the Psychiatric Department of the University of Bonn, Germany; in neurology at the Neurological Department of the University of Heidelberg in Mannheim; and psychotherapeutic and psychoanalytic training at the Ausbildungsinstitut für Psychotherapie und Psychoanalyse in Heidelberg/Mannheim, Germany.
Dr. Kasper published 945 in ISI (http://portal.isiknowledge.com) listed publications (Citation Index: 13.042, Hirsch-Index: 61) and more than 200 book chapters, in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Furthermore, he has conducted studies in psychopathological as well as clinical areas. Dr Kasper is a frequent national and international speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia.
Dr. Kasper serves/served on the executive committees and advisory boards of several national and international societies, such as the European College of Neuropsychopharmacology (ECNP) and the European Psychiatric Association (EPA). He has been elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2016. Moreover Dr. Kasper is Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He is Founding President of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP) and of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB). Furthermore, he is an Honorary Member of the Czech and Romanian Societies of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Royal College of Psychiatrists, UK, as well as of the Ukrainian Association of Psychiatry. Furthermore, he has been appointed Honorary Professor at the University of Hong Kong, China in 2005. In 1997, he was President of the 10th ECNP Congress, was Chairman of the Local Organizing Committee of the WPA Thematic Conference in 2004 and Co-Chair of the Local Organizing Committee of the WFSBP Congress 2005 and in 2007 Local Advisor for the ECNP congress in Vienna. In 2009, he was President of the WFSBP Congress in Paris. From 2005 to 2009 Dr. Kasper was President of the World Federation of Societies of Biological Psychiatry (WFSBP) and has been appointed as honorary president of the WFSBP in 2013.
Dr. Kasper serves on the editorial boards of numerous learned journals (total 53), including Journal of Clinical Psychiatry, CNS Spectrums, Journal of Affective Disorders, Pharmacopsychiatry, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the World Journal of Biological Psychiatry and the International Journal of Psychiatry in Clinical Practice, and Field Editor of the International Journal of Neuropsychopharmacology.
As a result of his research expertise he is the recipient of numerous national and international scientific and public awards and prizes and has recently been acknowledged with the Commander’s Cross II-nd class of the Republic of Austria.
Past President – Prof. John H. Krystal, USA
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry, and Professor of Neurobiology at the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published over 400 papers and reviews on the neurobiology and treatment of schizophrenia, alcoholism, post-traumatic stress disorder, and depression. His research program unites psychopharmacology, neuroimaging, and molecular genetics. His work on brain glutamate systems contributed to the identification of novel treatment mechanisms for depression, alcoholism, and schizophrenia that are now in development. He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal received a number of awards including the Joel Elkes Award of the American College of Neuropsychopharmacology, the Anna-Monika Foundation Prize for Depression Research, and the NIAAA Jack Mendelson Alcoholism Research Award. He is also a member of the Institute of Medicine of the U.S. National Academy of Sciences. He was Chairman of the NIMH Board of Scientific Counselors (2004-2007), served on the NIAAA National Alcohol Advisory Council (2008-2012), and president of the American College of Neuropsychopharmacology (2012). Since 2006, he edited a leading psychiatry and neuroscience journal, Biological Psychiatry (IF=9.25).
President Elect – Prof. Pierre Blier, Canada
Dr. Blier is a Full Professor of the Departments of Psychiatry and Cellular & Molecular Medicine, at the University of Ottawa, and Director of the Mood Disorders Research Program at the University of Ottawa Institute of Mental Health Research, Royal Ottawa Mental Health Care Center.
Dr. Blier is on the editorial boards of nine journals, the field editor for Translational Medicine for International Journal of Neuropsychopharmacology, and the Editor for the Americas of the Journal of Psychopharmacology. Has published over 450 abstracts and 270 peer-reviewed articles (h factor of 73) and has given lectures worldwide. He has a basic research laboratory investigating mechanisms of action of psychotropic medications, carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.
Dr. Blier has received several awards including the Canada Research Chair in Psychopharmacology (2004-2018) from the Government of Canada and the biennial CINP Basic Research Award in 2010.
Vice President – Prof. Shih-Ku Lin, Taiwan
Dr Shih-Ku Lin graduated from Kaohsiung Medical University in 1981, and received his psychiatric residency training in Taipei City Psychiatric Center (TCPC). After completing the training and acquired Board Certified Psychiatrist qualification, he had his fellowship of child psychiatry at Kansas University Medical Center in 1988. In 1993, he was appointed as the Chief of Department of Addiction Science at TCPC and has led this department for 11 years. Currently he is the Chair of Department of Psychiatry, Taipei City Hospital and Psychiatric Center and adjunct associate professor, College of Medicine, Taipei Medical University.
Since his residency, he followed Professor Wen-Ho Chang in academic researches and participated in the founding of Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) and served the first secretary of this Society in 2002. Dr Lin also founded Taiwanese Society of Addiction and served the first President in 2008. Currently he is the President of TSBPN (2016-2019).
Dr Lin’s research interest includes psychopharmacology, focusing on ethnic differences in pharmacokinetics and new drug clinical trials. Currently he is in charge of Research on Asian Psychotropic Prescription Pattern (REAP BD and MS) which will involve 15 Asian Countries and Region, to survey the medications used in bipolar disorder, and the disorders using mood stabilizers other than bipolar disorder. In addictive disorders, his groups focus on methamphetamine-induced psychosis and ketamine use disorder, covers from genetic study to clinical interventions. He also has more than twenty years’ experiences in clinical trials, mostly for phase II or III global and regional new psychotropic drug development. Dr Lin has published more than one hundred and twenty peer reviewed papers and has reviewed articles for many international journals.
Secretary – Prof. Elias Eriksson, Sweden
Elias Eriksson began his studies in medicine at the University of Gothenburg in 1975. Having had his scientific training at the department of pharmacology, led by monoamine pioneer and Nobel prize winner Arvid Carlsson, Eriksson became Med Dr in 1985, associate professor in 1988 and researcher at the Swedish MRC in 2000. From 2001 he has been professor of pharmacology at the University of Gothenburg. Eriksson is the author of approximately 300 papers mainly in the fields of preclinical and clinical psychopharmacology and has been invited speaker at >100 scientific international meetings. He has been main supervisor for 18 PhD students. He has previously been chairman of the Swedish Society for Biological Psychiatry and the Swedish Serotonin Society and a board member of the Scandinavian College of Neuropsychopharmacology and the Swedish Schizophrenia Foundation. He is a member of the Scientific Council for Medicine and Health in Sweden and an honorary member of the Swedish Society for Biological Psychiatry and the Swedish Serotonin Society. Eriksson’s preclinical and clinical studies have mainly been related to the importance of monoamines for the treatment of psychiatric disorders. He and his co-workers were early advocates of a role for serotonin in the treatment of panic disorder, being involved in the first approval of an antidepressant (clomipramine) for this disorder, and the first to show serotonin reuptake inhibitors to exert a prompt and dramatic symptom reduction in premenstrual dysphoric disorder. They have conducted numerous preclinical and clinical studies aiming to shed light on why inhibition of the serotonin transporter causes symptom reduction in so many disparate conditions, some effects occurring early and some requiring weeks of treatment to be maximal. Eriksson and co-workers have also taken an interest in the on-‐going debate regarding the alleged ineffectiveness of antidepressants, publishing a number of patient-level meta-analyses suggesting the questioning of these drugs to be largely unfounded. Eriksson and co-workers have also studied dopaminergic receptors, and were, e.g., the first to establish the pharmacological similarities between D2 autoreceptors in brain and prolactin-‐regulating D2 receptors in the pituitary. Studying the influence of haloperidol on D2-‐ receptor-‐mediated regulation of prolactin release in vitro, they were also the first to provide functional evidence for the fact that a G protein-‐coupled receptor may be the subject of inverse agonism.
Treasurer – Prof. Kazutaka Ikeda, Japan
Dr. Kazutaka Ikeda is the Chair of the Department of Psychiatry and Behavioral Sciences at the Tokyo Metropolitan Institute of Medical Science. He graduated from the Faculty of Technology at The University of Tokyo (B.Eng.) in 1989 and obtained his M.Med degree from Osaka University in 1991 and Ph.D. degree from Niigata University in 1995. While in Prof. Mishina’s laboratory at Niigata University, he cloned cDNA for the NMDA GluN2D receptor channel subunit and produced mice that lacked this subunit. He also produced mice that lacked the glutamate GluD2 receptor channel subunit and revealed a pivotal role for this subunit in motor control. Furthermore, he started studies on the opioid system and G protein-activated inwardly rectifying potassium (GIRK) channels. As a research fellow at RIKEN Brain Science Institute (1995-2000), he continued opioid and GIRK research and started studies on the dopamine system. He was appointed Senior Research Fellow (2000), Acting Chair (2002), and Chair (2003) in the Department of Molecular Psychiatry, Tokyo Institute Psychiatry, and Leader of the Addiction Substance Project (2011) and Chair of the Department of Psychiatry and Behavioral Sciences at the Tokyo Metropolitan Institute of Medical Science (2015). While at these institutions, he continued studies on addiction, schizophrenia, analgesia, and neurodevelopmental disorders at the molecular, genetic, animal-behavioral, and clinical levels. He has approximately 300 publications on these topics in prominent scientific journals. He was awarded the Distinguished International Scientist Collaboration Program Award from the U.S. National Institute on Drug Abuse in 2004, among several other awards. He is serving as an Academic Editor of PLoS One, a Field Editor of Alcoholism: Clinical and Experimental Research, and an Editorial Board Member of several other journals. He has been a Fellow of CINP since 2010 and served as CINP Councillor (2016-2018). The Japanese Society of Neuropsychopharmacology (JSNP) has over 1300 members and is under the umbrella of CINP. He is currently President of JSNP (2016-2018). He is President-elect (2017-2018) of the Asian College of Neuropsychopharmacology (AsCNP), which has over 3000 members and is also under the umbrella of CINP. He is a member of the American College of Neuropsychopharmacolgy (since 2014). He is also a member of the Science Council of Japan (2014-2020).